ATE21624T1 - Mikroverkapslung wasserloeslicher polypeptide. - Google Patents

Mikroverkapslung wasserloeslicher polypeptide.

Info

Publication number
ATE21624T1
ATE21624T1 AT81305426T AT81305426T ATE21624T1 AT E21624 T1 ATE21624 T1 AT E21624T1 AT 81305426 T AT81305426 T AT 81305426T AT 81305426 T AT81305426 T AT 81305426T AT E21624 T1 ATE21624 T1 AT E21624T1
Authority
AT
Austria
Prior art keywords
water
microencapsulation
soluble polypeptides
soluble
biocompatable
Prior art date
Application number
AT81305426T
Other languages
German (de)
English (en)
Inventor
John Scott Kent
Lynda Mary Sanders
Danny Harvey Lewis
Thomas Robert Tice
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22772297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE21624(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syntex Inc filed Critical Syntex Inc
Application granted granted Critical
Publication of ATE21624T1 publication Critical patent/ATE21624T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT81305426T 1980-11-18 1981-11-17 Mikroverkapslung wasserloeslicher polypeptide. ATE21624T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20786480A 1980-11-18 1980-11-18
EP81305426A EP0052510B2 (en) 1980-11-18 1981-11-17 Microencapsulation of water soluble polypeptides

Publications (1)

Publication Number Publication Date
ATE21624T1 true ATE21624T1 (de) 1986-09-15

Family

ID=22772297

Family Applications (1)

Application Number Title Priority Date Filing Date
AT81305426T ATE21624T1 (de) 1980-11-18 1981-11-17 Mikroverkapslung wasserloeslicher polypeptide.

Country Status (15)

Country Link
EP (1) EP0052510B2 (OSRAM)
JP (1) JPS57118512A (OSRAM)
AT (1) ATE21624T1 (OSRAM)
AU (1) AU556754B2 (OSRAM)
CA (1) CA1176565A (OSRAM)
DE (2) DE3175230D1 (OSRAM)
HK (1) HK20489A (OSRAM)
IE (1) IE52003B1 (OSRAM)
IL (1) IL64298A (OSRAM)
MY (1) MY8700835A (OSRAM)
NL (1) NL930001I2 (OSRAM)
NZ (1) NZ198982A (OSRAM)
PH (1) PH19942A (OSRAM)
SG (1) SG94487G (OSRAM)
ZA (1) ZA817973B (OSRAM)

Families Citing this family (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
FR2537980B1 (fr) * 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
AU567155B2 (en) * 1983-04-15 1987-11-12 Damon Biotech Inc. Capsules for releasing core material at constant rate
US4652443A (en) * 1983-06-07 1987-03-24 Japan Atomic Energy Research Institute Slow-release composite and process for producing the same
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US5693343A (en) 1984-03-16 1997-12-02 The United States Of America As Represented By The Secretary Of The Army Microparticle carriers of maximal uptake capacity by both M cells and non-M cells
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
USRE40786E1 (en) 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US6217911B1 (en) 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US6410056B1 (en) 1984-03-16 2002-06-25 The United States Of America As Represented By The Secretary Of The Army Chemotherapeutic treatment of bacterial infections with an antibiotic encapsulated within a biodegradable polymeric matrix
DE3428372A1 (de) * 1984-08-01 1986-02-13 Hoechst Ag, 6230 Frankfurt Mikrokapseln von regulatorischen peptiden mit kontrollierter freisetzung, verfahren zu ihrer herstellung und injektionszubereitungen
CH660302A5 (fr) * 1984-10-17 1987-04-15 Debiopharm Sa Procede de micro-encapsulation en phase heterogene de substances medicamenteuses hydrosolubles.
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
US5169633A (en) * 1985-07-29 1992-12-08 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
US5137874A (en) * 1985-07-29 1992-08-11 American Cyanamid Co. Partially coated C10 -C20 fatty acid salts of peptides having molecular weights up to about 5,000
US5059422A (en) * 1985-07-29 1991-10-22 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
CH669506A5 (en) * 1986-01-13 1989-03-31 Hugo Degen Oscillating and reclining furniture
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
JP2526589B2 (ja) * 1986-08-08 1996-08-21 武田薬品工業株式会社 ペプチド含有マイクロカプセルおよびその製造法
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
ES2102347T3 (es) 1987-02-20 1997-08-01 Genentech Inc Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv.
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
US5000886A (en) * 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5212154A (en) * 1987-08-14 1993-05-18 Akzo N.V. Preparation for treating complications in diabetes
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
WO1989003678A1 (en) * 1987-10-30 1989-05-05 Stolle Research & Development Corporation Low residual solvent microspheres and microencapsulation process
DE3738228A1 (de) * 1987-11-11 1989-05-24 Hoechst Ag Verfahren zur herstellung von bioabbaubaren mikrokapseln wasserloeslicher peptide und proteine sowie nach diesem verfahren erhaltene mikrokapseln
DE3744329A1 (de) * 1987-12-28 1989-07-06 Schwarz Pharma Gmbh Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
US5271945A (en) * 1988-07-05 1993-12-21 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
ZA905327B (en) * 1989-07-07 1992-03-25 Sandoz Ltd Sustained release formulations of water soluble peptides
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
CH679207A5 (OSRAM) * 1989-07-28 1992-01-15 Debiopharm Sa
US5084443A (en) * 1989-12-04 1992-01-28 Biomeasure, Inc. Promoting expression of acetylcholine receptors with lhrh antagonist
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US6353030B1 (en) 1990-08-01 2002-03-05 Novartis Ag Relating to organic compounds
ZA918168B (en) * 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
DE4041563A1 (de) * 1990-12-22 1992-06-25 Sanol Arznei Schwarz Gmbh Verfahren zur herstellung wirkstoffhaltiger mikropartikel aus hydrolytisch abbaubaren polymeren
WO1992019263A1 (en) 1991-04-24 1992-11-12 The United States Of America, As Represented By The Secretary Of The Army Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
KR100259827B1 (ko) 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
WO1995006415A1 (en) 1993-08-30 1995-03-09 Baylor College Of Medicine Senescent cell-derived inhibitors of dna synthesis
US5258488A (en) * 1992-01-24 1993-11-02 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US5142023A (en) * 1992-01-24 1992-08-25 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US5247059A (en) * 1992-01-24 1993-09-21 Cargill, Incorporated Continuous process for the manufacture of a purified lactide from esters of lactic acid
US6005067A (en) 1992-01-24 1999-12-21 Cargill Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US5247058A (en) * 1992-01-24 1993-09-21 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US6326458B1 (en) 1992-01-24 2001-12-04 Cargill, Inc. Continuous process for the manufacture of lactide and lactide polymers
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
DE4223169C1 (de) 1992-07-10 1993-11-25 Ferring Arzneimittel Gmbh Verfahren zur Mikroverkapselung wasserlöslicher Wirkstoffe
JP2651320B2 (ja) * 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
EP0595030A3 (en) * 1992-10-01 1995-06-07 Tanabe Seiyaku Co Multi-core microspheres with delayed drug delivery and process for their manufacture.
US5338822A (en) * 1992-10-02 1994-08-16 Cargill, Incorporated Melt-stable lactide polymer composition and process for manufacture thereof
US6005068A (en) * 1992-10-02 1999-12-21 Cargill Incorporated Melt-stable amorphous lactide polymer film and process for manufacture thereof
AU5294893A (en) 1992-10-02 1994-04-26 Cargill Incorporated A melt-stable lactide polymer fabric and process for manufacture thereof
WO1994008090A1 (en) * 1992-10-02 1994-04-14 Cargill, Incorporated Paper having a melt-stable lactide polymer coating and process for manufacture thereof
UA61046C2 (en) 1992-12-07 2003-11-17 Takeda Chemical Industries Ltd Sustained-release preparation and method for its manufacture
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US6939546B2 (en) 1993-05-21 2005-09-06 The United States Of America As Represented By The Secretary Of The Army Model for testing immunogenicity of peptides
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
SK282231B6 (sk) * 1993-11-19 2001-12-03 Janssen Pharmaceutica N. V. Farmaceutický prostriedok na liečenie psychotických porúch
JP3717930B2 (ja) 1993-12-07 2005-11-16 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー Ｂｍｐ−１２、ｂｍｐ−１３およびそれらの腱誘導組成物
FR2713933B1 (fr) * 1993-12-16 1996-02-02 Rhone Merieux Méthode de superovulation des femelles bovines, méthode de mise en anoestrus et kit approprié.
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6855331B2 (en) 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6117455A (en) 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
US7033608B1 (en) 1995-05-22 2006-04-25 The United States Of America As Represented By The Secretary Of The Army “Burst-free” sustained release poly-(lactide/glycolide) microspheres
US6902743B1 (en) 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US5877224A (en) * 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
AU722884B2 (en) * 1996-01-24 2000-08-10 United States Government Represented By The Secretary Of The Army Novel "burst-free" sustained release poly-(lactide/glycolide) microspheres
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1998016511A1 (en) 1996-10-15 1998-04-23 Janssen Pharmaceutica N.V. Synthesis of cisapride
DE69730093T2 (de) 1996-10-31 2006-07-20 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter Freisetzung
US6171788B1 (en) 1997-01-28 2001-01-09 The Regents Of The University Of California Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6475724B1 (en) 1997-01-28 2002-11-05 The Regents Of The University Of California Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US7138511B1 (en) 1997-01-28 2006-11-21 The Regents Of The University Of California Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
JP2002537415A (ja) * 1999-02-19 2002-11-05 バイオサルフ アーゲー マイクロカプセルの製造のための生物分解性複合材料
DE60012557T2 (de) 1999-10-15 2005-08-04 Genetics Institute, LLC, Cambridge Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
TWI284048B (en) 2000-01-27 2007-07-21 Zentaris Ag Compressed microparticles for dry injection
KR100772950B1 (ko) 2000-08-07 2007-11-02 와꼬 쥰야꾸 고교 가부시키가이샤 젖산 중합체 및 이의 제조 방법
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
CA2449008A1 (en) 2001-06-01 2002-12-12 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
WO2003000156A1 (en) 2001-06-22 2003-01-03 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
TW200526267A (en) 2001-06-29 2005-08-16 Takeda Chemical Industries Ltd Controlled release composition and method of producing the same
CN1278675C (zh) 2001-07-10 2006-10-11 佳能株式会社 含聚羟基烷醇酸酯的粒状体及其制备方法
US20040191215A1 (en) * 2003-03-25 2004-09-30 Michael Froix Compositions for induction of a therapeutic response
JP2004331750A (ja) 2003-05-02 2004-11-25 Canon Inc ポリヒドロキシアルカノエートを含有する磁性構造体及びその製造方法ならびにその用途
DE602004005477T2 (de) 2003-09-12 2007-12-13 Wyeth Injizierbare feste Calciumphosphat-Stäbe zur Abgabe von osteogenen Proteinen
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
ES2536235T3 (es) 2004-04-15 2015-05-21 Alkermes Pharma Ireland Limited Dispositivo polimérico de liberación prolongada
DK2447252T3 (da) 2004-05-23 2020-03-16 Hmi Medical Innovations Llc Theramuteinmodulatorer
NZ582130A (en) * 2004-08-04 2011-11-25 Clinuvel Pharmaceuticals Ltd Methods of inducing melanogenesis in a subject
ES2255426B1 (es) 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
AU2005304435B8 (en) 2004-11-10 2011-06-23 Tolmar Therapeutics, Inc. A stabilized polymeric delivery system
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
MX2007016032A (es) 2005-06-21 2008-03-10 Xoma Technology Ltd Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
JP5072057B2 (ja) * 2005-08-22 2012-11-14 東ソー株式会社 微小流路構造体を用いたマイクロカプセルの製造方法
KR100722607B1 (ko) 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
JP5048773B2 (ja) 2006-08-09 2012-10-17 インターシア セラピューティクス，インコーポレイティド 浸透圧式デリバリーシステム及びピストンアセンブリー
EP2094246B1 (en) 2006-12-18 2020-04-01 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same
WO2008077145A2 (en) 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
CA2692171C (en) 2007-06-22 2019-10-22 Randolph Watnick Methods and uses thereof of prosaposin
JP5536666B2 (ja) 2007-12-20 2014-07-02 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー 痛風の治療のための方法
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
BRPI1009431A2 (pt) 2009-03-09 2016-03-01 Pronova Biopharma Norge As pré-concentrados farmacêuticos e de suplemento alimentar, sistemas de liberação de droga, método de tratamento de pelo menos um problema de saúde em sujeito em necessidade do mesmo e método e sistema
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
ES2363965B1 (es) 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
AU2010339794B2 (en) 2009-12-17 2016-09-22 Children's Medical Center Corporation Saposin-A derived peptides and uses thereof
JP2013515719A (ja) 2009-12-23 2013-05-09 デフィアンテ・ファルマセウティカ・ソシエダデ・アノニマ 循環器疾患の処置に有用な組み合わせ組成物
JP2013525271A (ja) 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
ES2383271B1 (es) 2010-03-24 2013-08-01 Lipotec S.A. Procedimiento de tratamiento de fibras y/o materiales textiles
US9993019B2 (en) 2010-03-26 2018-06-12 Philip Morris Usa Inc. Method for making particle of a hydrophobic additive and a polysaccharide coating and tobacco products containing particle of a hydrophobic additive and a polysaccharide coating
CN104203275A (zh) 2010-06-09 2014-12-10 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN103732222B (zh) 2011-05-11 2018-12-28 儿童医疗中心有限公司 修饰的生物素结合蛋白及其融合蛋白和应用
WO2013028541A1 (en) 2011-08-19 2013-02-28 Children's Medical Center Corporation Vegf-binding protein for blockade of angiogenesis
DE102011114864A1 (de) * 2011-10-05 2013-04-11 Acino Ag Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
WO2013072767A1 (en) 2011-11-18 2013-05-23 Pronova Biopharma Norge As Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
CN102488619B (zh) 2011-12-05 2014-08-06 上海交通大学 连续生产艾塞那肽微球的装置及控制微球释放速度的方法
CN102511790B (zh) * 2011-12-05 2013-07-24 山东好当家海洋发展股份有限公司 一种水产蛋白肽微胶囊的制备方法
CN104144946A (zh) 2011-12-19 2014-11-12 爱克索马美国有限责任公司 治疗痤疮的方法
EP3560509B1 (en) 2011-12-22 2024-01-31 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
CN104520321A (zh) 2012-01-09 2015-04-15 斯克利普斯研究所 超长互补决定区及其用途
EP3663314A1 (en) 2012-01-09 2020-06-10 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
WO2013150386A2 (en) 2012-04-04 2013-10-10 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
US9585896B2 (en) 2012-04-04 2017-03-07 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin D for psoriasis, and methods and uses thereof
JP6494527B2 (ja) 2013-02-07 2019-04-03 ザ チルドレンズ メディカル センター コーポレーション 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原
AU2014222389B2 (en) 2013-02-28 2018-11-29 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
WO2015010100A2 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
CA2924109A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
ES2741308T3 (es) 2013-10-15 2020-02-10 Scripps Research Inst Interruptores de células T con receptores de antígenos quiméricos y usos de los mismos
EP3057994B1 (en) 2013-10-15 2020-09-23 The Scripps Research Institute Peptidic chimeric antigen receptor t cell switches and uses thereof
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
EP2977758A1 (en) 2014-07-24 2016-01-27 Université De Nice Sophia Antipolis Methods and kits for monitoring membranous nephropathy
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
EP3283113A4 (en) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
EP3310376A4 (en) 2015-06-17 2019-01-23 The California Institute for Biomedical Research MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
MX2018014016A (es) 2016-05-16 2019-08-01 Intarcia Therapeutics Inc Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
CN110267982B (zh) 2016-10-19 2024-02-23 斯克利普斯研究所 具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
WO2019066649A1 (en) 2017-09-26 2019-04-04 Nanomi B.V. PROCESS FOR THE PREPARATION OF MICROPARTICLES BY A DOUBLE EMULSION TECHNIQUE
CA3103265A1 (en) 2018-06-12 2019-12-19 Angiex, Inc. Antibody-oligonucleotide conjugates
JP7765379B2 (ja) 2019-08-12 2025-11-06 ピュリノミア バイオテック， インコーポレイテッド Ｃｄ３９発現細胞のａｄｃｃ標的化を介してｔ細胞媒介性免疫応答を促進及び増強するための方法及び組成物
CN110585170A (zh) * 2019-09-17 2019-12-20 南京赛弗斯医药科技有限公司 一种采用3d打印制备的醋酸特利加压素注射用缓释微球及其制备方法
WO2021081440A2 (en) 2019-10-24 2021-04-29 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
JP7550474B2 (ja) 2019-12-31 2024-09-13 広州帝奇医薬技術有限公司 第３級アミン医薬組成物の工業化バッチ調製方法
US20250197525A1 (en) 2021-04-28 2025-06-19 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
AU2022289610A1 (en) 2021-06-09 2024-01-25 The Scripps Research Institute Long-acting dual gip/glp-1 peptide conjugates and methods of use
CN118354793A (zh) 2022-04-29 2024-07-16 普瑞诺生物科技公司 用于治疗嗜酸性粒细胞驱动的疾病和病症的方法和组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS5324423B2 (OSRAM) * 1972-04-29 1978-07-20
JPS5017525A (OSRAM) * 1973-06-14 1975-02-24
JPS5749532B2 (OSRAM) * 1974-03-19 1982-10-22
JPS5035158A (OSRAM) * 1973-07-24 1975-04-03
JPS5314072B2 (OSRAM) * 1973-09-29 1978-05-15
JPS5726506B2 (OSRAM) * 1974-03-08 1982-06-04
NZ181036A (en) * 1975-06-12 1978-12-18 A Schally Luteinising hormone releasing hormone analogues and intermediates therefor
US4010196A (en) * 1975-06-25 1977-03-01 American Home Products Corporation Linear polyester salts
US4211769A (en) * 1977-08-24 1980-07-08 Takeda Chemical Industries, Ltd. Preparations for vaginal administration
CH649217A5 (de) * 1977-08-25 1985-05-15 Sandoz Ag Bromocriptin enthaltende mikrokapseln.
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone

Also Published As

Publication number Publication date
EP0052510B2 (en) 1994-10-19
CA1176565A (en) 1984-10-23
NL930001I2 (nl) 1997-05-01
EP0052510A2 (en) 1982-05-26
AU7756081A (en) 1982-05-27
JPH0440329B2 (OSRAM) 1992-07-02
DE52510T1 (de) 1986-03-20
AU556754B2 (en) 1986-11-20
JPS57118512A (en) 1982-07-23
NZ198982A (en) 1985-05-31
NL930001I1 (nl) 1993-02-16
IE52003B1 (en) 1987-05-13
MY8700835A (en) 1987-12-31
SG94487G (en) 1988-05-06
HK20489A (en) 1989-03-17
ZA817973B (en) 1983-07-27
EP0052510B1 (en) 1986-08-27
IL64298A0 (en) 1982-02-28
EP0052510A3 (en) 1982-09-08
PH19942A (en) 1986-08-14
IL64298A (en) 1985-07-31
IE812695L (en) 1982-05-18
DE3175230D1 (en) 1986-10-02

Similar Documents

Publication Publication Date Title
ATE21624T1 (de) Mikroverkapslung wasserloeslicher polypeptide.
IL136054A0 (en) Poly(vinylamine) -based superabsorbent gels and method of manufacturing the same
ZA915584B (en) Drug delivery system involving interaction between protein or polypeptide and hydrophobic biodegradable polymer
EP0266119A3 (en) Method and formulation for orally administering bioactive agents to and through the peyer's patch
ES2056915T3 (es) Sistema de suministro de farmacos y metodo de fabricarlos.
DK0388220T3 (da) Præparater til vedvarende frigivelse af klorhexidin
DE69532444D1 (de) Modulierte freigabe aus bioverträglichen polymeren
NO954186L (no) Plaster med aktive bestanddeler
GR3030732T3 (en) Pharmaceutical compositions including a drug, a cross-linked polymeric substance, an oil, and a surface active agent.
CA2064889A1 (en) Polymeric materials
DK0904063T3 (da) Fremgangsmåde til fremstilling af mikropartikler
DE69014322D1 (de) Granulate, ihre Herstellung und Anwendung.
ATE361940T1 (de) Lagerstabile kationisch polymerisierende zubereitungen mit verbessertem härtungsverhalten
DE69020847D1 (de) Kern-Schalen-Polymer, Harzzusammensetzung und daraus geformte Gegenstände.
ES2073522T3 (es) Copolimeros de urea de poliuretano procesables en fusion y metodo para su preparacion.
EP0381529A3 (en) Air freshener
BR9104426A (pt) Metodo para impedir a alogmeracao de po,agente anti-aglomeracao e po
DE69825769D1 (de) Eingekapselte wasserdispergierbare perfluoroetherpolymere
IT8941633A0 (it) Procedimento per l'ottenimento di un biopolimero reticolato a base di collagene, impianto a base di questo biopolimero e procedimento per l'ottenimento dell'impianto.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time